Form 483

ONESOURCE SPECIALTY PHARMA LIMITED Form 483, 2016-03-16

FDA issued a Form 483 to ONESOURCE SPECIALTY PHARMA LIMITED on 2016-03-16 with 12 public-safe observations.

483· Form 483 issuedHuman Drugs12 observations

ONESOURCE SPECIALTY PHARMA LIMITED · Bengaluru, India · Issued March 16, 2016

Overview

  • 12 public-safe observations are available for this inspection.
  • 5 structured CFR citations are represented.
  • 3 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

16 Mar 2016
21 CFR 211.100(a)

Absence of Written Procedures

Cited by Sandra A Hughes, Steven P Donald, Marion Michaelis

16 Mar 2016
21 CFR 211.100(a)

Absence of Written Procedures

Cited by Sandra A Hughes, Steven P Donald, Marion Michaelis

16 Mar 2016
21 CFR 211.113(b)

Procedures for sterile drug products

Cited by Sandra A Hughes, Steven P Donald, Marion Michaelis

16 Mar 2016
21 CFR 211.188(b)

Batch production and Batch Control Record Requirements

Cited by Sandra A Hughes, Steven P Donald, Marion Michaelis

16 Mar 2016
21 CFR 211.192

Extent of discrepancy, failure investigations

Cited by Sandra A Hughes, Steven P Donald, Marion Michaelis

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.113(b)Cited across public-safe Form 483 observations4x
21 CFR 211.100(a)Cited across public-safe Form 483 observations2x
21 CFR 211.188(b)Cited across public-safe Form 483 observations2x
21 CFR 211.192Cited across public-safe Form 483 observations2x
21 CFR 211.42(c)(10)(v)Cited across public-safe Form 483 observations2x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 12 observations

The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere